MoonLake Stock Jumps 23%. Why a $3 Billion Merck Offer Could Be a Win-Win. - Barron's
1. Merck submitted a $3 billion nonbinding offer for MoonLake. 2. MoonLake shares surged 23% following the acquisition news. 3. Merck faces a patent cliff with Keytruda losing exclusivity in 2028. 4. Analysts are very bullish on MoonLake with a target price of $79. 5. MoonLake has no drugs on the market but progressing in trials.